BCR and B-cell chronic lymphocytic leukemia: Intriguingly, links between BCR signaling, activation of translation, and efficacy of ibrutinib have already been well characterized in the context of CLL76, where it was hypothesized that efficacy of ibrutinib may be in part linked to its inadvertent MYC modulation, in the sense that MYC translation is an essential oncogenic mechanism downstream of BCR signaling in CLL.